180 related articles for article (PubMed ID: 37822941)
21. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Hua RH; Zhang SJ; Niu B; Ge JY; Lan T; Bu ZG
Microbiol Spectr; 2023 Aug; 11(4):e0119023. PubMed ID: 37306579
[TBL] [Abstract][Full Text] [Related]
22. An engineered bispecific human monoclonal antibody against SARS-CoV-2.
Li Z; Li S; Zhang G; Peng W; Chang Z; Zhang X; Fan Z; Chai Y; Wang F; Zhao X; Li D; Zhang R; He Z; Zou W; Xu K; Lei W; Liu P; Hao J; Zhang J; Sun L; Wu G; Tan S; Gao GF; Gao F; Wu Y
Nat Immunol; 2022 Mar; 23(3):423-430. PubMed ID: 35228696
[TBL] [Abstract][Full Text] [Related]
23. A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022.
Yu K; Liu B; Yu H; Sun C; Wang X; Li G; Dong M; Wang Y; Zhang J; Xu N; Liu W
Front Cell Infect Microbiol; 2023; 13():1155293. PubMed ID: 37207187
[TBL] [Abstract][Full Text] [Related]
24. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
25. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
26. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124
[TBL] [Abstract][Full Text] [Related]
28. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
29. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
30. The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility.
Chang MR; Ke H; Losada Miguéns L; Coherd C; Nguyen K; Kamkaew M; Johnson R; Storm N; Honko A; Zhu Q; Griffiths A; Marasco WA
Protein Eng Des Sel; 2023 Jan; 36():. PubMed ID: 37561410
[TBL] [Abstract][Full Text] [Related]
31. Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19.
Matveev AL; Pyankov OV; Khlusevich YA; Tyazhelkova OV; Emelyanova LA; Timofeeva AM; Shipovalov AV; Chechushkov AV; Zaitseva NS; Kudrov GA; Yusubalieva GM; Yussubaliyeva SM; Zhukova OA; Tikunov AY; Baklaushev VP; Sedykh SE; Lifshits GI; Tikunova NV
Biochemistry (Mosc); 2023 Sep; 88(9):1205-1214. PubMed ID: 37770389
[TBL] [Abstract][Full Text] [Related]
32. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
[TBL] [Abstract][Full Text] [Related]
33. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.
Du W; Jiang P; Li Q; Wen H; Zheng M; Zhang J; Guo Y; Yang J; Feng W; Ye S; Kamara S; Jiang P; Chen J; Li W; Zhu S; Zhang L
Microbiol Spectr; 2023 Feb; 11(1):e0356222. PubMed ID: 36511681
[TBL] [Abstract][Full Text] [Related]
34. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.
Ku Z; Xie X; Lin J; Gao P; Wu B; El Sahili A; Su H; Liu Y; Ye X; Tan EY; Li X; Fan X; Goh BC; Xiong W; Boyd H; Muruato AE; Deng H; Xia H; Zou J; Kalveram BK; Menachery VD; Zhang N; Lescar J; Shi PY; An Z
Nat Commun; 2022 Sep; 13(1):5552. PubMed ID: 36138032
[TBL] [Abstract][Full Text] [Related]
35. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
36. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
[TBL] [Abstract][Full Text] [Related]
37. Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo.
Wang Q; Peng L; Nie Y; Shu Y; Zhang H; Song Z; Li Y; Hu H; Li L; Wang X; Liu J; Li J; Shi Z; Deng F; Guo Y; Zhou Y; Yan B; Hu Z; Wang M
Virol Sin; 2023 Apr; 38(2):257-267. PubMed ID: 36596381
[TBL] [Abstract][Full Text] [Related]
38. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
[TBL] [Abstract][Full Text] [Related]
39. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
40. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
